Coronary Syndrome

Cardiovascular·MeSH: Angina, Unstable

13 drugs in development·9 companies·1 clinical trial

Drug Pipeline by Phase

Approved(7)

Drug	Company
clopidogrel bi	Teva Pharmaceutical Industries Limited (TEVA)
clopidogrel bi	DR REDDYS LABORATORIES LTD (RDY)
prasugrel	Mylan II B.V. (MYL)
ticagrelor	Mylan II B.V. (MYL)
ticagrelor	DR REDDYS LABORATORIES LTD (RDY)
ticagrelor	Amneal Pharmaceuticals, Inc. (AMRX)
tirofiban	NEXUS BIOPHARMA INC (NEXS)

Phase 3(2)

Drug	Company
milvexian	GH Research PLC (GHRS)
pelacarsen	Novartis AG (NVS)

Phase 1(1)

Drug	Company
aem-28	Capstone Holding Corp. (CAPS)

Preclinical(1)

Drug	Company
aem-28-08	Capstone Holding Corp. (CAPS)

Phase 4(2)

Drug	Company
Colchicine 0.6 mg	Cidara Therapeutics, Inc. (CDTX)
Rivaroxaban 2.5 mg	Cidara Therapeutics, Inc. (CDTX)

BioSniper tracks 13 drugs in development for Coronary Syndrome across 9 companies.

There are 1 clinical trial targeting Coronary Syndrome tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.